SLC5A2 and hydrops fetalis: The EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) trial was the first study that evaluated the efficacy of an SGLT2 inhibitor in patients with HF with mildly reduced (HFmrEF) and HF with preserved ejection fraction (HFpEF).47 The trial enrolled a total of 5,988 patients with HF and LVEF > 40% with NYHA II and NYHA III symptoms.